Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146928 | 0.97 | TSHR (0.53) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL5645150 | 0.94 | TSHR (0.50) | TSHRACHEALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL541709 | 0.94 | TSHR (0.50) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL29083664 | 0.94 | TSHR (0.50) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL31457202 | 0.94 | TSHR (0.50) | TSHRACHEALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL29042332 | 0.92 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL3223494 | 0.92 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| Bromide SCHEMBL29042359 | 0.92 | TSHR (0.47) | TSHRACHEALDH1A1CA1CA2 | |
| Propane SCHEMBL29069359 | 0.89 | TSHR (0.45) | TSHRACHEALDH1A1CA1CA2 | |
| SCHEMBL3632065 | 0.87 | ACHE (0.43) | TSHRACHEALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010004278-A1 | METHOD FOR INCREASING THE ENANTIOMERIC EXCESS OF CHIRAL PHOSPHINE OXIDES, SULPHIDES, IMIDES AND BORANES | CELTIC CATALYSTS LIMITED (IE) | 2010-01-14 | — | — | WO | claimed |
| US-9707553-B2 | P-chirogenic organophosphorus compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-18 | — | — | US | disclosed |
| EP-3150613-A1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-04-05 | — | — | EP | disclosed |
| EP-2731956-B1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | CENTRE NAT RECH SCIENT (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-20160023199-A1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | SYNTHELOR SAS (FR) | 2016-01-28 | — | — | US | disclosed |
| US-9186661-B2 | P-chirogenic organophosphorus compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2015-11-17 | — | — | US | disclosed |
| EP-2297170-B1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS, NOVEL CARBONYLATION LIGANDS AND CATALYST SYSTEMS INCORPORATING SUCH LIGANDS | LUCITE INT UK LTD (GB) | 2015-09-09 | — | — | EP | disclosed |
| US-8816113-B2 | Process for the carbonylation of ethylenically unsaturated compounds, novel carbonylation ligands and catalyst systems incorporating such ligands | LUCITE INTERNATIONAL UK LIMITED (GB) | 2014-08-26 | — | — | US | disclosed |
| US-20140142325-A1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 2014-05-22 | — | — | US | disclosed |
| US-8053604-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-08 | — | — | US | disclosed |
| EP-2297170-A1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS, NOVEL CARBONYLATION LIGANDS AND CATALYST SYSTEMS INCORPORATING SUCH LIGANDS | Lucite International UK Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | SPERA PHARMA, INC. (JP) | 2010-05-20 | — | — | US | disclosed |
| US-7678942-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-16 | — | — | US | disclosed |
| WO-2010004278-A1 | METHOD FOR INCREASING THE ENANTIOMERIC EXCESS OF CHIRAL PHOSPHINE OXIDES, SULPHIDES, IMIDES AND BORANES | CELTIC CATALYSTS LIMITED (IE) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010001174-A1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS, NOVEL CARBONYLATION LIGANDS AND CATALYST SYSTEMS INCORPORATING SUCH LIGANDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2010-01-07 | — | — | WO | disclosed |
| EP-1452537-B1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | SPERA PHARMA, INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | SPERA PHARMA, INC. (JP) | 2005-02-03 | — | — | US | disclosed |
| EP-1452537-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | Takeda Chemical Industries, Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | H1-10, ITPA, RER1 | TSHR 1063/4885ACHE 1352/4885ALDH1A1 4580/4885 |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | BACE1, H1-10, PRMT1 | TSHR 1972/4885ACHE 7/4885ALDH1A1 2206/4885 |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | H1-10, ITPA, RER1 | TSHR 1089/4885ACHE 1361/4885ALDH1A1 4580/4885 |
| US-20160023199-A1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | ACHE, PTMS, DDT | TSHR 3601/4885ACHE 1/4885ALDH1A1 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.